AbbVie Inc. is in talks to acquire mental health therapeutics company Gilgamesh Pharmaceuticals in a deal highlighting ...

AbbVie Inc. (NYSE:ABBV) is one of the top low volatility healthcare stocks to buy now. In a report released on July 22, Vamil ...

AbbVie Inc. (NYSE:ABBV) is one of the best long term low volatility stocks to buy now. On July 10, Morgan Stanley analyst ...

The fact that multiple AbbVie Inc. ( NYSE:ABBV ) insiders offloaded a considerable amount of shares over the past ...

According to the update, the $823 million expense is related to acquired IPR&D, typically incurred through collaborations, ...

AbbVie reported revenues of $14.46 billion in the last reported quarter, representing a year-over-year change of +4.3%. EPS of $2.65 for the same period compares with $2.91 a year ago.

AbbVie Inc. (NYSE:ABBV) is a research-based biopharmaceutical company. The one-month return of AbbVie Inc. (NYSE:ABBV) was 0.79%, and its shares gained 14.87% of their value over the last 52 weeks.

Following a national competition, AbbVie (ABBV) and SpinUp – the University of Toronto's lab-based, life sciences accelerator – announce Neuropeutics Inc as recipient of first AbbVie Biotech ...

Glenmark, through wholly-owned subsidiary IGI Therapeutics SA, announced an exclusive licensing agreement with AbbVie for ISB ...

AbbVie Inc. (NYSE: ABBV) is reportedly negotiating the acquisition of Gilgamesh Pharmaceuticals, a privately held mental ...